| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Journal of Clinical Endocrinology & Metabolism, Vol 77, 956-962, Copyright © 1993 by Endocrine Society
ARTICLES |
K Mulligan, C Grunfeld, MK Hellerstein, RA Neese and M Schambelan
Division of Endocrinology, San Francisco General Hospital, California 94110.
Body wasting, characterized by disproportionate loss of body cell mass, is a feature of many chronic diseases, including infection with the human immunodeficiency virus (HIV). Therapies that merely increase energy intake do not consistently restore body cell mass in patients with the wasting syndrome. Because treatment with GH has induced nitrogen (N) retention in catabolic patients after surgery, burns, cancer, and hypocaloric feeding, we designed this study to determine whether GH could also produce an anabolic response in persons with HIV- associated weight loss. Six HIV-positive (HIV+) men with an average weight loss of 19% and six healthy weight-stable controls (HIV-) were hospitalized on a metabolic ward, where they consumed a constant metabolic diet during successive 5-day precontrol, 7-day baseline, and 7-day treatment [recombinant human GH (rhGH), 0.1 mg/kg.day] periods. The effects of rhGH on body weight, N and electrolyte excretion, energy expenditure, substrate oxidation, and integrated lipid and carbohydrate metabolism were assessed. Body weight increased promptly and progressively during treatment (2.0 +/- 0.3 and 1.6 +/- 0.2 kg in HIV+ and HIV-, respectively). Urinary N excretion decreased by 288 +/- 17 and 287 +/- 42 mmol/day in HIV+ and HIV-, respectively. Resting energy expenditure increased by 7.5% in both groups. Protein oxidation decreased, whereas lipid oxidation increased significantly. Glucose flux increased, and modest increases in fasting plasma triglyceride, glucose, and insulin levels were observed. Thus, short term rhGH treatment increased both protein anabolism and protein-sparing lipid oxidation, effects that should increase body cell mass if sustained during chronic therapy.
This article has been cited by other articles:
 |
|
 |
|
  A. S Wierzbicki, S. D Purdon, T. C Hardman, R. Kulasegaram, and B. S Peters Review: Clinical aspects of the management of HIV lipodystrophy The British Journal of Diabetes & Vascular Disease, May 1, 2008; 8(3): 113 - 119. [Abstract] [PDF]
|
|
|
|
 |
|
 K. K. Miller, B. M. K. Biller, A. Schaub, K. Pulaski-Liebert, G. Bradwin, N. Rifai, and A. Klibanski Effects of Testosterone Therapy on Cardiovascular Risk Markers in Androgen-Deficient Women with Hypopituitarism J. Clin. Endocrinol. Metab., July 1, 2007; 92(7): 2474 - 2479. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Strle, S. R. Broussard, R. H. McCusker, W.-H. Shen, J. M. LeCleir, R. W. Johnson, G. G. Freund, R. Dantzer, and K. W. Kelley C-Jun N-Terminal Kinase Mediates Tumor Necrosis Factor-{alpha} Suppression of Differentiation in Myoblasts Endocrinology, September 1, 2006; 147(9): 4363 - 4373. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. R. Spollett Hyperglycemia in HIV/AIDS Diabetes Spectr, July 1, 2006; 19(3): 163 - 166. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. W. Storer, L. J. Woodhouse, F. Sattler, A. B. Singh, E. T. Schroeder, K. Beck, M. Padero, P. Mac, K. E. Yarasheski, P. Geurts, et al. A Randomized, Placebo-Controlled Trial of Nandrolone Decanoate in Human Immunodeficiency Virus-Infected Men with Mild to Moderate Weight Loss with Recombinant Human Growth Hormone as Active Reference Treatment J. Clin. Endocrinol. Metab., August 1, 2005; 90(8): 4474 - 4482. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. J Batterham Investigating heterogeneity in studies of resting energy expenditure in persons with HIV/AIDS: a meta-analysis Am. J. Clinical Nutrition, March 1, 2005; 81(3): 702 - 713. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A Wainberg, B. G. Brenner, E. Daar, J. M. Gertner, C. Olivier, and S. Kenley Lack of Effect of Recombinant Human Growth Hormone on the In Vitro Activities of Antiretroviral Drugs against Human Immunodeficiency Virus Type 1 Antimicrob. Agents Chemother., June 1, 2004; 48(6): 2337 - 2340. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Q. He, E. S. Engelson, J. B. Albu, S. B. Heymsfield, and D. P. Kotler Preferential loss of omental-mesenteric fat during growth hormone therapy of HIV-associated lipodystrophy J Appl Physiol, May 1, 2003; 94(5): 2051 - 2057. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. S. Hardin, K. J. Ellis, M. Dyson, J. Rice, R. McConnell, and D. K. Seilheimer Growth Hormone Decreases Protein Catabolism in Children with Cystic Fibrosis J. Clin. Endocrinol. Metab., September 1, 2001; 86(9): 4424 - 4428. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. C. Lo, K. Mulligan, M. A. Noor, J.-M. Schwarz, R. A. Halvorsen, C. Grunfeld, and M. Schambelan The Effects of Recombinant Human Growth Hormone on Body Composition and Glucose Metabolism in HIV-Infected Patients with Fat Accumulation J. Clin. Endocrinol. Metab., August 1, 2001; 86(8): 3480 - 3487. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Colson, A. Le Cam, D. Maiter, M. Edery, and J.-P. Thissen Potentiation of Growth Hormone-Induced Liver Suppressors of Cytokine Signaling Messenger Ribonucleic Acid by Cytokines Endocrinology, October 1, 2000; 141(10): 3687 - 3695. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Mulligan, V. W. Tai, and M. Schambelan Use of Growth Hormone and Other Anabolic Agents in AIDS Wasting JPEN J Parenter Enteral Nutr, November 1, 1999; 23(6_suppl): S202 - S209. [Abstract] [PDF]
|
|
|
|
 |
|
 C. Corcoran and S. Grinspoon Treatments for Wasting in Patients with the Acquired Immunodeficiency Syndrome N. Engl. J. Med., June 3, 1999; 340(22): 1740 - 1750. [Full Text] [PDF]
|
|
|
|
 |
|
 K. L. Johansen, K. Mulligan, and M. Schambelan Anabolic Effects of Nandrolone Decanoate in Patients Receiving Dialysis: A Randomized Controlled Trial JAMA, April 14, 1999; 281(14): 1275 - 1281. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Strawford, T. Barbieri, M. Van Loan, E. Parks, D. Catlin, N. Barton, R. Neese, M. Christiansen, J. King, and M. K. Hellerstein Resistance Exercise and Supraphysiologic Androgen Therapy in Eugonadal Men With HIV-Related Weight Loss: A Randomized Controlled Trial JAMA, April 14, 1999; 281(14): 1282 - 1290. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Grinspoon, C. Corcoran, T. Stanley, L. Katznelson, and A. Klibanski Effects of Androgen Administration on the Growth Hormone-Insulin-Like Growth Factor I Axis in Men with Acquired Immunodeficiency Syndrome Wasting J. Clin. Endocrinol. Metab., December 1, 1998; 83(12): 4251 - 4256. [Abstract] [Full Text]
|
|
|
|
 |
|
 S. Jain, D. W. Golde, R. Bailey, and M. E. Geffner Insulin-Like Growth Factor-I Resistance Endocr. Rev., October 1, 1998; 19(5): 625 - 646. [Abstract] [Full Text]
|
|
|
|
|
|
M. A. McNurlan, P. J. Garlick, R. A. Frost, K. A. DeCristofaro, C. H. Lang, R. T. Steigbigel, J. Fuhrer, and M. Gelato Albumin Synthesis and Bone Collagen Formation in Human Immunodeficiency Virus-Positive Subjects: Differential Effects of Growth Hormone Administration J. Clin. Endocrinol. Metab., September 1, 1998; 83(9): 3050 - 3055. [Abstract] [Full Text]
|
|
|
|
|
|
X. Y. Shen, R. I. G. Holt, J. P. Miell, S. Justice, B. Portmann, M.-C. Postel-Vinay, and R. J. M. Ross Cirrhotic Liver Expresses Low Levels of the Full-Length and Truncated Growth Hormone Receptors J. Clin. Endocrinol. Metab., July 1, 1998; 83(7): 2532 - 2538. [Abstract] [Full Text]
|
|
|
|
 |
|
 S. M. Arpadi, M. N. B. Horlick, J. Wang, P. Cuff, M. Bamji, and D. P. Kotler Body Composition in Prepubertal Children With Human Immunodeficiency Virus Type 1 Infection Arch Pediatr Adolesc Med, July 1, 1998; 152(7): 688 - 693. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Mulligan, V. W. Tai, and M. Schambelan Effects of Chronic Growth Hormone Treatment on Energy Intake and Resting Energy Metabolism in Patients with Human Immunodeficiency Virus-Associated Wasting--A Clinical Research Center Study J. Clin. Endocrinol. Metab., May 1, 1998; 83(5): 1542 - 1547. [Abstract] [Full Text]
|
|
|
|
 |
|
 P. J. Garlick, M. A. McNurlan, T. Bark, C. H. Lang, and M. C. Gelato Hormonal Regulation of Protein Metabolism in Relation to Nutrition and Disease J. Nutr., February 1, 1998; 128(2): 356 - 356. [Abstract] [Full Text]
|
|
|
|
 |
|
 L Burdet, B de Muralt, Y Schutz, C Pichard, and J. Fitting Administration of growth hormone to underweight patients with chronic obstructive pulmonary disease. A prospective, randomized, controlled study Am. J. Respir. Crit. Care Med., December 1, 1997; 156(6): 1800 - 1806. [Abstract] [Full Text]
|
|
|
|
|
|
S. Grinspoon, C. Corcoran, K. Miller, B. M. K. Biller, H. Askari, E. Wang, J. Hubbard, E. J. Anderson, N. Basgoz, H. M. Heller, et al. Body Composition and Endocrine Function in Women with Acquired Immunodeficiency Syndrome Wasting J. Clin. Endocrinol. Metab., May 1, 1997; 82(5): 1332 - 1337. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Stenlof, J.-O. Johansson, L. Lonn, L. Sjostrom, and B.-A. Bengtsson Diurnal Variations in Twenty-Four-Hour Energy Expenditure During Growth Hormone Treatment of Adults with Pituitary Deficiency J. Clin. Endocrinol. Metab., April 1, 1997; 82(4): 1255 - 1260. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-P. Thissen and J. Verniers Inhibition by Interleukin-1{beta} and Tumor Necrosis Factor-{alpha} of the Insulin-Like Growth Factor I Messenger Ribonucleic Acid Response to Growth Hormone in Rat Hepatocyte Primary Culture Endocrinology, March 1, 1997; 138(3): 1078 - 1084. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Fields-Gardner Invited Review: A Review of Mechanisms of Wasting in HIV Disease Nutr Clin Pract, October 1, 1995; 10(5): 167 - 176. [Abstract] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |
